
ACT Brief: Community Research Financing Gaps, Neuroscience Endpoint Data, and Teva’s Biosimilar Deal
11/4/2026
0:00
1:57
In today’s ACT Brief, we examine why community research needs lasting financing and infrastructure, how electronic outcome tools can strengthen neuroscience endpoints, and how Teva is licensing two biosimilars from Samsung Bioepis.
More episodes from "Applied Clinical Trials"



Don't miss an episode of “Applied Clinical Trials” and subscribe to it in the GetPodcast app.








